

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
20 FEB 14 PM 4:07

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pfizer, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 325 7th Street, N.W. Suite 1200 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name M. Kenneth Bowler Telephone (202) 783-7070 E-mail (optional) _____			5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31354000

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,880,000.00</u> Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature M. Kenneth Bowler Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 1 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues

H.R. 1906 and S. 1233, Agriculture Appropriations, (FDA Funding and Risk Assessment for Animal Drugs)

Animal Health Issues

Antibiotic Resistance

CVM Proposed Framework for Evaluating and Assuring the Human Safety of Microbial Effects of New Animal Drugs

Intended for use in Food-Producing Animals

17. House(s) of Congress and Federal agencies contacted Check if None

Food & Drug Administration

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 2 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

- H.R. 1906/S. 1233, Agriculture Appropriations, (FDA Funding and Animal Health Issues)
- H.R. 2084, S. 1143, Transportation Appropriations, (Study on Nonsedating Medications)
- H.R. 2670, S. 1217, Commerce, Justice, State Appropriations, (New York Botanical Gardens)
- H.R. 2684, VA/HUD Appropriations, (VA Healthcare System Reform and Drug Formulary)
- H.R. 3064, Labor/HHS Appropriations, (Medicaid Pharmaceutical Coverage and NIH Funding Issues)
- H.R. 3194, Omnibus Appropriations Bill, (tax issues)

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Department of State
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Yes
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 3 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)
16. Specific Lobbying issues
H.R. 1598 and S. 1172, "The Patent Fairness Act", (patent term restoration)
H.R. 1907, "The American Inventors Protection Act", (patent term restoration and Patent Office reforms)
Amendments to Hatch-Waxman Act (no bills)
Intellectual Property Protection Issues (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None
- Congressional Budget Office
Department of Commerce
Department of State
House of Representatives
Patent and Trademark Office
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 4 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues
H.R. 1875, S. 353, Class Action Jurisdiction Act
H.R. 2245, S. 1214, Federal Preemption Bill

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bennett, Catherine P.</u>		<u>No</u>
<u>Bowler, M. Kenneth</u>		<u>No</u>
<u>Boyd, Michael D.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 5 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)
16. Specific Lobbying issues
S. 1090, H.R. 1300, Superfund Reauthorization
S. 547, H.R. 2520, "Credit for Voluntary Reductions Act"
"Brownfield" redevelopment issues (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bowler, M. Kenneth</u>		<u>No</u>
<u>Boyd, Michael D.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 6 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FIN (one per page)

16. Specific Lobbying issues
H.R. 887, No Title – Requires additional disclosure of corporate charitable contributions. (disclosure requirements)

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 7 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 1885, S. 1191, "The International Prescription Drug Parity Act", (product safety)
- H.R. 2116, S. 1076, "Veterans' Millenium Health Care Act", (system reform issues)
- H.R. 2763, Internet Pharmacy Consumer Protection Act, (consumer protection issues)
- H.R. 358, S. 1256, H.R. 448, S. 326, Health Care/Managed Care Bills, (pharmaceutical issues)
- H.R. 664, S. 731, "The Prescription Drug Fairness for Seniors Act of 1999", (government price controls)
- S. 1462, Bill to permit importation of medicines from Canada, (product safety)
- S. 2927, Affordable Prescription Drugs Act, (intellectual property issues)
- S. 881, H.R. 2404, H.R. 2470, S. 573, H.R. 1057, Confidentiality of Medical Information, (research issues)
- OMB Circular A-110, HHS Proposed Regulations for "Standards for Privacy of Individually Identifiable Health Information." (research issues)

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services
Department of Veterans Affairs
Executive Office of the President
Food & Drug Administration
General Accounting Office
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 8 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Item	Description	Date
17a	House of Congress/Agencies	National Institutes of Health
17a	House of Congress/Agencies	Senate

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

S. 1837, S. 1725, S. 1480, H.R. 2782, H.R. 2925, Medicare Prescription Drug Benefit Bills, (drug benefit)

S. 841, H.R. 1495, H.R. 1796, H.R. 1109, Medicare Prescription Drug Benefit Bills, (drug benefit)

Breaux/Thomas Premium Support for Medicare Proposal (drug benefit)

President Clinton's Plan for Strengthening and Modernizing Medicare for the 21st Century (drug benefit)

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 10 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R. 1980, Workplace Fairness Act, (R&D Tax Credit)

H.R. 2488, Financial Freedom Act of 1999, (R&D Tax Credit, Issues affecting international tax, Medicare prescription drug provision)

H.R. 3194, Omnibus Appropriations Act, (R&D Tax Credit)

H.R. 3197, Bill to prevent abuse of tax deduction for charitable contribution of drugs

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Treasury
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2009

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 11 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Item	Description	Data
16	Lobbying issues	Tax Reform issues (no bills) Foreign Tax Deferral (no bills) Foreign Tax Credit (no bills) Section 936 (no bills) Issues affecting international tax [Notice 98-11, 904(g)] (no bills)

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRA (one per page)
16. Specific lobbying issues
H.R. 2084, S. 1143, Transportation Appropriations, (Study on Nonsedating Medications)
DOT Study of Safe Use of Medications by Commercial Truck Drivers

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Boyd, Michael D.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2009

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 13 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

- H.J. Res. 58, Resolution of Disapproval of Jackson-Vanik Waiver for Vietnam.
- H.J. Res. 57, Resolution of Disapproval of Normal Trade Relations for China.
- H.R. 1885, S. 1191, "The International Prescription Drug Parity Act", (drug safety)
- H.R. 434, S. 1387, Africa Free Trade Bill, (pharmaceutical issues)
- International intellectual property protection issues (no bills)
- WTO implementation issues (no bills)
- International pharmaceutical market access issues (no bills)
- WTO Ministerial issues (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Agriculture
- Department of State
- Department of Transportation
- Department of Treasury
- Executive Office of the President
- House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/12/2000

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations Page 14 of 15

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Item	Description	Data
17a	House of Congress/Agencies	Senate
17a	House of Congress/Agencies	United States Trade Representative